Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

British Medical Journal

- PMLiVE

UCB reveals positive phase 3 results for Bimzelx in moderate-to-severe plaque psoriasis

Affecting 90% of psoriasis patients, the chronic autoimmune disease causes red, itchy, scaly patches

- PMLiVE

Almirall gains rights to Eloxx’s rare dermatological disease asset in deal worth over $470m

ZKN-013 is designed to overcome nonsense mutations in rare skin diseases such as junctional epidermolysis bullosa

- PMLiVE

J&J and Protagonist’s JNJ-2113 shown to maintain skin clearance in plaque psoriasis

More than 125 million people worldwide are estimated to be living with the immune-mediated skin disorder

- PMLiVE

Almirall gains rights to Novo Nordisk’s IL-21 blocker for dermatological diseases

NN-8828 has been developed up to phase 2 in non-dermatological indications

- PMLiVE

Almirall and CRG partner to advance therapeutic approaches for atopic dermatitis

The inflammatory skin disease currently affects an estimated 4.4% of adults in the EU

- PMLiVE

Almirall and Microsoft partner to accelerate digital transformation in medical dermatology

The alliance is aimed at advancing the research of solutions for dermatological diseases

- PMLiVE

Bristol Myers Squibb’s Sotyktu accepted by SMC for plaque psoriasis

More than 133,520 people in Scotland are affected by the inflammatory condition

- PMLiVE

Almirall and etherna partner to develop mRNA-based therapies for severe skin diseases

Dermatological diseases are estimated to affect 1.8 billion people worldwide

- PMLiVE

Almirall, BSC and Nostrum Biodiscovery partner for dermatological diseases

The collaboration will aim to find new therapies for dermatological diseases through AI

- PMLiVE

Almirall granted EC approval for Ebglyss in moderate-to-severe atopic dermatitis

The inflammatory skin disease currently affects an estimated 4.4% of adults in the EU

- PMLiVE

Almirall and Absci announce $650m AI dermatological drug discovery partnership

The collaboration expands Absci’s de novo AI drug creation portfolio into dermatology

- PMLiVE

World Psoriasis Day: Almirall highlights impact of disease on patient well-being

Almost 77% of patients believe that psoriasis negatively affects their daily life and well-being

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links